Elixiron is a privately-held biotechnology company with operations in San Francisco, Taipei and Shanghai on a mission to develop next-generation immunotherapies for neurodegenerative and immunological disorders, as well as cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/24/21 | $27,000,000 | Series A-1 Extension |
CDIB Venture Capital DCI Partners Fubon Financial Holdings Hong Tai Electric Industrial Mega International Commercial Bank Pangu Capital  | undisclosed |
